IN2014MN01469A - - Google Patents
Info
- Publication number
- IN2014MN01469A IN2014MN01469A IN1469MUN2014A IN2014MN01469A IN 2014MN01469 A IN2014MN01469 A IN 2014MN01469A IN 1469MUN2014 A IN1469MUN2014 A IN 1469MUN2014A IN 2014MN01469 A IN2014MN01469 A IN 2014MN01469A
- Authority
- IN
- India
- Prior art keywords
- derivative
- modulation
- processes
- formula
- preparation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Anesthesiology (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161579613P | 2011-12-22 | 2011-12-22 | |
| GBGB1122113.2A GB201122113D0 (en) | 2011-12-22 | 2011-12-22 | Novel compounds |
| PCT/GB2012/053233 WO2013093496A1 (en) | 2011-12-22 | 2012-12-21 | 2 - (pyridin- 2yl) - 1, 7 -diaza-spiro [4.4] nonane- 6 -one compound as voltage-gated sodium channels modulator |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN01469A true IN2014MN01469A (enEXAMPLES) | 2015-04-17 |
Family
ID=45572877
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1469MUN2014 IN2014MN01469A (enEXAMPLES) | 2011-12-22 | 2012-12-21 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US9376436B2 (enEXAMPLES) |
| EP (2) | EP2797922B1 (enEXAMPLES) |
| JP (2) | JP2015502394A (enEXAMPLES) |
| KR (1) | KR20140113692A (enEXAMPLES) |
| CN (1) | CN104271581B (enEXAMPLES) |
| AU (1) | AU2012356386A1 (enEXAMPLES) |
| BR (1) | BR112014014940A2 (enEXAMPLES) |
| CA (1) | CA2858938C (enEXAMPLES) |
| EA (1) | EA026500B1 (enEXAMPLES) |
| ES (1) | ES2581327T3 (enEXAMPLES) |
| GB (1) | GB201122113D0 (enEXAMPLES) |
| HK (2) | HK1203492A1 (enEXAMPLES) |
| IL (1) | IL233215A0 (enEXAMPLES) |
| IN (1) | IN2014MN01469A (enEXAMPLES) |
| MX (1) | MX2014007637A (enEXAMPLES) |
| SG (1) | SG11201403356YA (enEXAMPLES) |
| WO (2) | WO2013093497A1 (enEXAMPLES) |
| ZA (1) | ZA201404269B (enEXAMPLES) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201122113D0 (en) * | 2011-12-22 | 2012-02-01 | Convergence Pharmaceuticals | Novel compounds |
| GB201209015D0 (en) | 2012-05-22 | 2012-07-04 | Convergence Pharmaceuticals | Novel compounds |
| RU2650523C1 (ru) * | 2017-07-24 | 2018-04-16 | федеральное государственное автономное образовательное учреждение высшего образования "Казанский (Приволжский) федеральный университет" (ФГАОУ ВО КФУ) | Производное пиридоксина для лечения эпилепсии |
| EP3694510A4 (en) | 2017-10-10 | 2021-06-30 | Biogen Inc. | SPIRO DERIVATIVE PREPARATION PROCESS |
| WO2019097318A1 (en) | 2017-11-17 | 2019-05-23 | Cellix Bio Private Limited | Compositions and methods for the treatment of eye disorders |
| CN113563258A (zh) * | 2021-07-29 | 2021-10-29 | 派普医药(江苏)有限公司 | 一种4-溴-2-(二氟甲基)-5-甲基吡啶的制备方法 |
| WO2023044364A1 (en) | 2021-09-15 | 2023-03-23 | Enko Chem, Inc. | Protoporphyrinogen oxidase inhibitors |
| AU2022349463A1 (en) * | 2021-09-24 | 2024-03-14 | Xenon Pharmaceuticals Inc. | Pyridinyl derivatives as sodium channel activators |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5474995A (en) | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
| US5466823A (en) | 1993-11-30 | 1995-11-14 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides |
| PL185510B1 (pl) | 1995-02-13 | 2003-05-30 | Searle & Co | Nowa pochodna podstawionego izoksazolu i środek farmaceutyczny |
| US5633272A (en) | 1995-02-13 | 1997-05-27 | Talley; John J. | Substituted isoxazoles for the treatment of inflammation |
| UA57002C2 (uk) | 1995-10-13 | 2003-06-16 | Мерк Фросст Кенада Енд Ко./Мерк Фросст Кенада Енд Сі. | Похідне (метилсульфоніл)феніл-2-(5н)-фуранону, фармацевтична композиція та спосіб лікування |
| ES2194195T3 (es) | 1996-04-12 | 2003-11-16 | Searle & Co | N-((4-(5-metil-3-fenililxazol-4-il)fenil)sulfonilpropanamida y su sal sodica como profarmacos de inhibnidores de cox-2. |
| KR100371620B1 (ko) | 1996-07-18 | 2003-05-09 | 머크 프로스트 캐나다 앤드 캄파니 | 선택적인 사이클로옥시게나제-2 억제제로서의 치환된 피리딘 |
| CO4960662A1 (es) | 1997-08-28 | 2000-09-25 | Novartis Ag | Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados |
| ATE317845T1 (de) | 1997-09-05 | 2006-03-15 | Glaxo Group Ltd | Pharmazeutische zusammensetzung, enthaltend 2,3- diaryl-pyrazolo(1,5-b)pyridazin derivate |
| EP1127058B1 (en) | 1998-11-03 | 2004-09-01 | Glaxo Group Limited | Pyrazolopyridine derivatives as selective cox-2 inhibitors |
| US6025683A (en) | 1998-12-23 | 2000-02-15 | Stryker Corporation | Motor control circuit for regulating a D.C. motor |
| ATE261444T1 (de) | 1999-02-27 | 2004-03-15 | Glaxo Group Ltd | Pyrazolopyridine |
| GB0003224D0 (en) | 2000-02-11 | 2000-04-05 | Glaxo Group Ltd | Chemical compounds |
| GB0021494D0 (en) | 2000-09-01 | 2000-10-18 | Glaxo Group Ltd | Chemical comkpounds |
| GB0323204D0 (en) | 2003-10-03 | 2003-11-05 | Novartis Ag | Organic compounds |
| SE0302811D0 (sv) * | 2003-10-23 | 2003-10-23 | Astrazeneca Ab | Novel compounds |
| TW200728258A (en) | 2005-10-10 | 2007-08-01 | Glaxo Group Ltd | Novel compounds |
| GB0520578D0 (en) * | 2005-10-10 | 2005-11-16 | Glaxo Group Ltd | Novel compounds |
| TW200730494A (en) | 2005-10-10 | 2007-08-16 | Glaxo Group Ltd | Novel compounds |
| US8143306B2 (en) | 2005-10-10 | 2012-03-27 | Convergence Pharmaceuticals Limited | Methods of treating bipolar disorders |
| US7855218B2 (en) | 2005-10-10 | 2010-12-21 | Convergence Pharmaceuticals Limited | Compounds |
| US7505330B2 (en) * | 2006-08-31 | 2009-03-17 | Micron Technology, Inc. | Phase-change random access memory employing read before write for resistance stabilization |
| CN101641099A (zh) | 2007-01-24 | 2010-02-03 | 葛兰素集团有限公司 | 包含3,5-二氨基-6-(2,3-二氯苯基)-1,2,4-三嗪或r(-)-2,4-二氨基-5-(2,3-二氯苯基)-6-氟甲基嘧啶和nk1的药物组合物 |
| GB0701366D0 (en) | 2007-01-24 | 2007-03-07 | Glaxo Group Ltd | Novel pharmaceutical compositions |
| GB0701365D0 (en) | 2007-01-24 | 2007-03-07 | Glaxo Group Ltd | Novel pharmaceutical compositions |
| GB0706630D0 (en) | 2007-04-04 | 2007-05-16 | Glaxo Group Ltd | Novel compounds |
| US8759542B2 (en) | 2009-09-14 | 2014-06-24 | Convergence Pharmaceuticals Limited | Process for preparing alpha-carboxamide derivatives |
| ES2467166T3 (es) * | 2009-10-14 | 2014-06-12 | Xenon Pharmaceuticals Inc. | Métodos de síntesis de compuestos de espiro-oxindol |
| GB201122113D0 (en) * | 2011-12-22 | 2012-02-01 | Convergence Pharmaceuticals | Novel compounds |
| GB201209015D0 (en) | 2012-05-22 | 2012-07-04 | Convergence Pharmaceuticals | Novel compounds |
-
2011
- 2011-12-22 GB GBGB1122113.2A patent/GB201122113D0/en not_active Ceased
-
2012
- 2012-12-21 CN CN201280070485.0A patent/CN104271581B/zh not_active Expired - Fee Related
- 2012-12-21 EA EA201491251A patent/EA026500B1/ru unknown
- 2012-12-21 EP EP12810416.3A patent/EP2797922B1/en not_active Not-in-force
- 2012-12-21 MX MX2014007637A patent/MX2014007637A/es unknown
- 2012-12-21 US US14/365,372 patent/US9376436B2/en not_active Expired - Fee Related
- 2012-12-21 BR BR112014014940A patent/BR112014014940A2/pt not_active Application Discontinuation
- 2012-12-21 JP JP2014548201A patent/JP2015502394A/ja active Pending
- 2012-12-21 IN IN1469MUN2014 patent/IN2014MN01469A/en unknown
- 2012-12-21 EP EP12810417.1A patent/EP2794612B1/en not_active Not-in-force
- 2012-12-21 KR KR1020147019965A patent/KR20140113692A/ko not_active Withdrawn
- 2012-12-21 HK HK15103930.0A patent/HK1203492A1/xx unknown
- 2012-12-21 SG SG11201403356YA patent/SG11201403356YA/en unknown
- 2012-12-21 JP JP2014548202A patent/JP2015502395A/ja active Pending
- 2012-12-21 CA CA2858938A patent/CA2858938C/en active Active
- 2012-12-21 ES ES12810416.3T patent/ES2581327T3/es active Active
- 2012-12-21 AU AU2012356386A patent/AU2012356386A1/en not_active Abandoned
- 2012-12-21 US US14/365,391 patent/US9303032B2/en not_active Expired - Fee Related
- 2012-12-21 WO PCT/GB2012/053234 patent/WO2013093497A1/en active Application Filing
- 2012-12-21 WO PCT/GB2012/053233 patent/WO2013093496A1/en active Application Filing
- 2012-12-21 HK HK15104075.3A patent/HK1203501A1/xx unknown
-
2014
- 2014-06-10 ZA ZA2014/04269A patent/ZA201404269B/en unknown
- 2014-06-18 IL IL233215A patent/IL233215A0/en unknown
-
2016
- 2016-02-25 US US15/053,445 patent/US20160185758A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013093496A1 (en) | 2013-06-27 |
| US9303032B2 (en) | 2016-04-05 |
| EP2797922A1 (en) | 2014-11-05 |
| GB201122113D0 (en) | 2012-02-01 |
| SG11201403356YA (en) | 2014-07-30 |
| WO2013093497A1 (en) | 2013-06-27 |
| ES2581327T3 (es) | 2016-09-05 |
| KR20140113692A (ko) | 2014-09-24 |
| ZA201404269B (en) | 2016-06-29 |
| EP2794612A1 (en) | 2014-10-29 |
| MX2014007637A (es) | 2014-09-26 |
| HK1203492A1 (en) | 2015-10-30 |
| HK1203501A1 (en) | 2015-10-30 |
| JP2015502395A (ja) | 2015-01-22 |
| CA2858938C (en) | 2020-03-10 |
| CA2858938A1 (en) | 2013-06-27 |
| JP2015502394A (ja) | 2015-01-22 |
| IL233215A0 (en) | 2014-08-31 |
| US9376436B2 (en) | 2016-06-28 |
| EA201491251A1 (ru) | 2014-11-28 |
| US20160185758A1 (en) | 2016-06-30 |
| BR112014014940A2 (pt) | 2017-06-13 |
| CN104271581B (zh) | 2016-08-31 |
| EP2794612B1 (en) | 2016-04-06 |
| EA026500B1 (ru) | 2017-04-28 |
| CN104271581A (zh) | 2015-01-07 |
| AU2012356386A1 (en) | 2014-07-10 |
| US20140350040A1 (en) | 2014-11-27 |
| US20150225400A1 (en) | 2015-08-13 |
| EP2797922B1 (en) | 2016-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014MN01469A (enEXAMPLES) | ||
| IN2014MN02459A (enEXAMPLES) | ||
| PH12015502839B1 (en) | Antiviral compounds | |
| MX344530B (es) | Compuestos de benceno substituido. | |
| MX2013010170A (es) | Moduladores heterociclicos de sintesis lipidica. | |
| EA028156B9 (ru) | Конденсированные гетероциклические соединения в качестве модуляторов ионных каналов | |
| GEP201706695B (en) | Substituted 4-phenyl-pyridi-nes for the treatment of nk-1 receptor related diseases | |
| MX2013014843A (es) | Oxazepinas como moduladores del canal de iones. | |
| MX2020012695A (es) | Compuestos de benceno substituidos con arilo o heteroarilo. | |
| PH12013502565A1 (en) | Substituted imidazopyridinyl-aminopyridine compounds | |
| IN2014MN00988A (enEXAMPLES) | ||
| MX346375B (es) | Antagonistas de espiro-oxindol de mdm2. | |
| PH12014501514A1 (en) | New azetidine derivatives, pharmaceutical compositions and uses thereof | |
| NZ705213A (en) | C17-heteroaryl derivatives of oleanolic acid and methods of use thereof | |
| IN2015DN01151A (enEXAMPLES) | ||
| IN2014DN06104A (enEXAMPLES) | ||
| GEP20156372B (en) | Pyridazinone compounds and their use as daao inhibitors | |
| HK1211947A1 (en) | Fluorinated epoxyketone-based compounds and uses thereof as proteasome inhibitors | |
| MX2015003701A (es) | Composiciones para tratamiento. | |
| MX2014002446A (es) | Compuestos de ciclohexano sustituidos novedosos. | |
| IN2014MN02393A (enEXAMPLES) | ||
| MX347541B (es) | Analogos de acido sialico. | |
| IN2015DN00085A (enEXAMPLES) | ||
| NZ720807A (en) | Fused heterocyclic compounds as ion channel modulators | |
| IN2013MU02279A (enEXAMPLES) |